Targeting Tumor Angiogenesis with the Selective VEGFR-3 Inhibitor EVT801 in Combination with Cancer Immunotherapy.
Michael R PaillasseMichael EsquerréFlorie A BertrandCéline Poussereau-PomiéMélanie PicheryVirgile VisentinGeneviève Gueguen-DorbesFlorence GaujarenguesPauline BarronGaelle BadetAnne BriauxPierre-Benoit AnceyDavid SibracEric ErdociainDennis ÖzcelikJérôme MeneyrolValérie MartinAnne Gomez-BrouchetJanik SelvesPhilippe RochaixMaxime BattistellaCéleste LebbéJean-Pierre DelordFrédérique Dol-GleizesFrançoise BonoIsabelle BlancAntoine AlamIan HunneyballMark WhittakerPierre FonsPublished in: Cancer research communications (2022)
The VEGFR-3 inhibitor EVT801 demonstrates superior selectivity and toxicity profile than other VEGFR-3 tyrosine kinase inhibitors. EVT801 showed potent antitumor effects in VEGFR-3-positive tumors, and tumors with VEGFR-3-positive microenvironments through blood vessel homogenization, and reduction of tumor hypoxia and limited immunosuppression. EVT801 increases immune checkpoint inhibitors' antitumor effects.